Along with continued levels of growth, the one thing I’ll be looking out for is whether they have the runway to raise again only after FDA approval. If that’s the case there’ll be no more cheap shares before we see a hugely accretive event with the associated speculation before hand. Plus infant app launching side-by-side.
Things could good take off very quickly. Exciting times ahead.
